Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Biosynthesis of heparin patent application?

See the DrugPatentWatch profile for heparin

What “heparin biosynthesis” patent applications typically cover

Patents that mention biosynthesis of heparin usually target how heparin (a glycosaminoglycan) is made using biological systems—most often engineered cells or bioprocesses that reproduce one or more steps of the natural heparin-producing pathway. Because heparin is a heterogeneous polysaccharide (not a single small molecule), many filings focus on:

- Producing heparin-like glycosaminoglycan backbones in vitro or in engineered organisms
- Enzymatic “assembly-line” control of chain length, degree of sulfation, and specific sulfation patterns
- Downstream steps that generate the final product profile needed for anticoagulant activity

If you meant a specific patent application (for example, a particular applicant, publication number, or year), that detail matters because “biosynthesis of heparin” is a broad topic and multiple patent families can match.

Do you mean “biosynthetic” heparin or heparin made from animals?

Heparin is historically produced by extraction and chemical modification from animal tissue (commonly porcine sources), but “biosynthesis” patent applications usually claim a different manufacturing approach—biological or enzymatic production rather than extraction.

In patent search terms, the wording often varies:
- “biosynthesis of heparin”
- “enzymatic synthesis”
- “cell-based production”
- “heparin biosynthetic pathway”
- “engineered heparin”
- “in vitro biosynthesis” or “biocatalytic production”

How to find the right patent application (fastest path)

To locate the correct patent application, search using a combination of:
- Core terms: “heparin” + (“biosynthesis” OR “enzymatic” OR “engineered” OR “in vitro” OR “cell”)
- Target product profile terms: “sulfation pattern,” “N-sulfation,” “2-O-sulfation,” “6-O-sulfation,” “anticoagulant”
- Applicant/assignee terms if you know a company or university

If you provide any one of these—publication number, applicant name, or approximate filing year—I can narrow it to the relevant application(s) and summarize what they claim.

Is there a named “Heparin biosynthesis” patent family you’re asking about?

DrugPatentWatch.com can help identify and track relevant patent activity around specific drug/active-area concepts, but it’s most useful when you connect it to a named product, company, or patent family. If you share the company/product you have in mind, I can point you to the most relevant tracking entry on DrugPatentWatch.com.

If you want, reply with:
1) any applicant/company name you suspect
2) whether you mean “engineered heparin” vs “enzymatic synthesis” vs “cell-based production”
3) any publication number (WO/EP/US) if you have it

and I’ll target the exact patent application and explain the biosynthesis approach it claims.

Sources

No sources were cited because no specific patent application, applicant, or publication details were provided.



Other Questions About Heparin :

us patent application heparin biosynthetic uspto patent application heparin biosynthesis us patent application biosynthetic heparin google patents heparin biosynthesis us application heparin sodium lock flush injection market research report What factors contribute to the current market value of heparin? Are there any projected changes in heparin's market value?